About this trial

The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for cytomegalovirus in haploid hematopoietic stem cell transplantation(haplo-HSCT) .

Eligibility criteria

Qualifiers

All patients were diagnosed with hemopathy.

All patients should have the indication of Haploidentical hematopoietic stem cell transplant and receive the prophylaxis for cytomegalovirus.

All patients should sign an informed consent document indicating that they understand the purpose of and procedures required for the study and be willing to participate in the study.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • CMV/EBV-CMI

Treatment groups

No treatment groups listed

Locations

1
First Affiliated Hospital of Soochow University215006, SuzhouJiangsu, China

Sponsors and collaborators

The First Affiliated Hospital of Soochow University

Lead sponsor